Clinical Trial Update: Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating isatuximab in combination with lenalidomide and dexamethasone for high-risk smoldering multiple myeloma; currently listed as active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)
• SARCLISA (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING